All In Biotech

Drug Trial Radar · NCT03536117

Dose-Defining Safety and Immunogenicity Study of MTBVAC in South African Neonates

Phase 2a Dose-Defining Safety and Immunogenicity Study of MTBVAC in South African Neonates Living in a High-Burden Tuberculosis-Endemic Region

Last checked: Nov 19, 2026Latest source record: Apr 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

99

Actual

Start

Feb 12, 2019

Primary completion

May 17, 2022

Study completion May 17, 2022

Sponsor

Lead sponsor
Biofabri, S.LIndustry
Sponsor type
Industry
Collaborators
South African Tuberculosis Vaccine Initiative; Universidad de Zaragoza; TuBerculosis Vaccine Initiative
First posted
May 24, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, up to 96 hours
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A Phase 2a dose-defining study of MTBVAC to evaluate the safety, reactogenicity, immunogenicity, and potential for IGRA conversion and reversion, of MTBVAC in South African newborns. Ninety-nine HIV unexposed, BCG naïve newborns will be randomized to receive either BCG 2.5 x 105 CFU (n=24) or MTBVAC at one of three dose levels (n=75). Allocation will be double blind. Enrolment will be sequential into 3 cohorts of increasing MTBVAC dose (Cohort 1: n=25 MTBVAC 2.5 x 10E+04 and n=8 BCG; Cohort 2: n=25 MTBVAC 2.5 x 10E+05 and n=8 BCG; Cohort 3: n=25 MTBVAC 2.5 x 10E+06 and n=8 BCG). Dose escalation will be staggered to allow gradual evaluation of safety; final selection of the dose for Cohort 3 will be based on all available safety and immunogenicity data.

Conditions

  • Tuberculosis

Interventions

  • MTBVACBiological

    Live-attenuated Mycobacterium tuberculosis based on the deletion of phoP and fadD26 virulence genes

  • BCGBiological

    Live-attenuated Mycobacterium bovis obtained by subculture passaging in ox-bile and glycerated potatoes between 1908-1921 by Albert Calmette and Camille Guerin. BCG is the only licensed vaccine today against tuberculosis (TB) mainly used in TB-endemic countries.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with treatment-related adverse events as defined in protocol.Time frame: 365 days post-vaccination
  2. Immunogenicity analysis in infantsTime frame: 365 days post-vaccination

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • SATVI: Worcester

    Worcester, Western Cape, South Africa

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.